There were more serious side effects in the Herceptin group than in the observation group.

The SPOT-Light test can measure how many HER2 genes are present in a sample of breast tumor; the more genes there are, the more likely the tumor will respond to treatment with Herceptin.

The researchers then looked at the drug Herceptin, which is used to treat HER2-positive breast cancer.